The Safety and Cardiovascular Event Efficacy of Bococizumab in High-Risk Patients (SPIRES) Trial showed that persistent elevation of high-sensitivity C-reactive protein (hs-CRP) at 14 weeks was associated with increased future cardiovascular events, even after low levels of low-density lipoprotein cholesterol (LDL-C) were achieved.

Authors

• Person: Not available Organization: National Lipid Association
  EBM Tools for Practice: Best Biomarkers for Inflammation

Sources

• EBM Tools for Practice: Best Biomarkers for Inflammation www.lipid.org National Lipid Association via serper

Referenced by nodes (3)

• high-sensitivity C-reactive protein concept
• cardiovascular events concept
• low-density lipoprotein cholesterol concept